Completed PHASE2 INTERVENTIONAL 2-arm NCT05086276

FX-322 in Adults With Acquired Sensorineural Hearing Loss

A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Multicenter Study to Evaluate the Efficacy of FX-322 Administered by Intratympanic Injection in Adults With Acquired Sensorineural Hearing Loss

Sponsor: Frequency Therapeutics

Conditions Hearing Loss, Sensorineural Noise Induced Hearing Loss Sudden Hearing Loss

Interventions FX-322 Placebo

Updated 14 times since 2021 Last updated: Apr 20, 2023 Started: Oct 12, 2021 Primary completion: Dec 30, 2022 Completion: Dec 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hearing Loss, Sensorineural and Noise Induced Hearing Loss, this trial is completed. The trial is conducted by Frequency Therapeutics and has accumulated 14 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

14 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2023 — Jul 2024 [monthly]

Completed PHASE2
Apr 2023 — May 2023 [monthly]

Completed PHASE2

▶ Show 9 earlier versions

Feb 2023 — Apr 2023 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Nov 2022 — Feb 2023 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE2
Jun 2022 — Sep 2022 [monthly]

Recruiting PHASE2
May 2022 — Jun 2022 [monthly]

Recruiting PHASE2
Mar 2022 — May 2022 [monthly]

Recruiting PHASE2
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE2
Dec 2021 — Feb 2022 [monthly]

Recruiting PHASE2
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE2

First recorded

Oct 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Frequency Therapeutics

Data source: Frequency Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Amherst, United States , Charleston, United States , Cincinnati, United States , Colorado Springs, United States , Dallas, United States , Fort Worth, United States , Fresno, United States , Marrero, United States , Milwaukee, United States and 16 more locations